Evaluating the impact of peer supported mass Hepatitis C screening initiative in prisoners. by Crowley, D et al.
 Crowley, D, Murtagh, R, Cullen, W, Keevans, M, Laird, E, McHugh, T, 
McKiernan, S, Miggin, SJ, O'Reilly, D, Betts Symonds, G, Tobin, C, van Hout, 
MC and Lambert, J
 Evaluating the impact of peer supported mass Hepatitis C screening initiative 
in prisoners.
http://researchonline.ljmu.ac.uk/id/eprint/10978/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Crowley, D, Murtagh, R, Cullen, W, Keevans, M, Laird, E, McHugh, T, 
McKiernan, S, Miggin, SJ, O'Reilly, D, Betts Symonds, G, Tobin, C, van 
Hout, MC and Lambert, J Evaluating the impact of peer supported mass 
Hepatitis C screening initiative in prisoners. Harm Reduction Journal. ISSN 
LJMU Research Online
http://researchonline.ljmu.ac.uk/
RESEARCH Open Access
Evaluating peer-supported screening as a
hepatitis C case-finding model in prisoners
Desmond Crowley1,2* , Ross Murtagh2, Walter Cullen2, Mary Keevans3, Eamon Laird4, Tina McHugh5,
Susan McKiernan6, Sarah Jayne Miggin6, Eileen O’Connor2,5, Deirdre O’Reilly3, Graham Betts-Symonds7,
Ciara Tobin8, Marie Claire Van Hout9 and John S. Lambert2,5
Abstract
Background: Hepatitis C Virus (HCV) infection is endemic in prison populations, and HCV management in prisons is
suboptimal. Incarceration is a public health opportunity to target this cohort. Community peer support increases
HCV screening and treatment uptake. Prison peer workers have the potential to support the engagement of
prisoners with health services and reduce stigma. This study’s primary aim is to evaluate peer-supported screening
as a model of active HCV case finding with a secondary aim to describe the HCV cascade among those infected
including linkage to care and treatment outcomes.
Methods: An observational study was conducted in a medium-security Irish male prison housing 538 inmates,
using a risk-based questionnaire, medical records, peer-supported screening, laboratory-based HCV serology tests
and mobile elastography.
Results: A prison peer-supported screening initiative engaged large numbers of prisoners in HCV screening (n =
419). The mean age of participants was 32.8 years, 92% were Irish and 33% had a history of injecting drug use.
Multiple risk factors for HCV acquisition were identified including needle sharing (16%). On serological testing, 87
(21%) were HCV Ab +ve and 50 (12%) were HCV RNA +ve of whom 80% were fibroscaned (25% showing evidence
of liver disease). Eighty-six percent of those with active infection were linked with HCV care, with 33% undergoing
or completing treatment. There was a high concordance with HCV disclosure at committal and serological testing
(96% for HCV Ab +ve and 89% for HCV Ab −ve).
Conclusion: Peer-supported screening is an effective active HCV case-finding model to find and link prisoners with
untreated active HCV infection to HCV care.
Keywords: HCV, Hepatitis C virus, Screening, Peer-support, Prison, PWID
Background
Untreated hepatitis C viral (HCV) infection poses a major
public health problem and is endemic in prison popula-
tions globally [1, 2]. Prisoners have multiple risk factors
for HCV acquisition, the most important being unsafe
injecting drug use (IDU), a risk which can exist both in
the community and while incarcerated [2–5].
Prison offers an ideal opportunity to target this hard-to-
reach group with screening and other healthcare interven-
tions [6–8]. The identification, treatment and prevention
of HCV infection in prison populations is a public health
priority [4, 9–11] The WHO and other HCV guidelines
recommend universal HCV screening for all prisoners [8,
12–16]. Reviews of HCV screening in prisons globally are
rare [9, 17], but where available, they show that despite
most prisons offering HCV screening, uptake is poor, and
standardized protocols for HCV management are the ex-
ception [9, 10, 17]. Because most prison sentences are of
short duration, HCV linkage to care poses an additional
challenge [4, 18, 19].
A number of successful strategies have been shown to
increase HCV screening uptake in prisoners. These in-
clude the introduction of opt-out rather than an opt-in
policy for screening, the use of point of care testing (POC)
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and dried blood spot testing (DBS) and the targeted
screening of at-risk persons on committal (on entry) [9,
10, 17, 20–23]. The uptake of risk-based screening is
dependent on prisoners admitting to a history of IDU with
its associated stigma, a recognised barrier to both HCV
screening and treatment [24].
Recent guidance from the European Centre for Dis-
ease Prevention and Control (ECDC) and the Euro-
pean Centre for Monitoring of Drugs and Drug
Addiction (EMCDDA) advises that HCV screening be
offered to all prisoners and concludes that provider-
initiated screening strategies yield a higher uptake
than client-initiated strategies [25]. A 2017 systematic
review found that HCV screening at prison entry was
associated with higher uptake compared to testing
during incarceration or pre-release [10]. This review
also reported that the use of peer education had a
positive impact on the uptake of HIV screening [26].
Of the 600,000 people incarcerated in European
prisons at any given time, 3400 are in Irish prisons [18].
Studies on Irish prisoners report high rates of opiate use
(50 %), IDU (43%) and HCV infection (13%) [27, 28]. Re-
cent national HCV screening guidelines recommend the
screening of all prisoners and re-screening annually with
targeted screening if an HCV transmission risk is identi-
fied [16]. HCV treatment in Irish prisons is provided by
specialist services. Ireland, like other developed coun-
tries, has a large proportion of undiagnosed and un-
treated HCV-infected individuals incarcerated in its
prisons [16].
The study site is one of three locations where in-reach
hepatology services, through specialist nurses, are pro-
vided in the IPS. HCV direct-acting antivirals (DAA)
have been available in Ireland since 2014, with initial
availability restricted to cases clinical need (including for
prisoners) for budgetary reasons. These restrictions were
lifted in 2018, and now DAA including 8-week pan-
genotypic regimens can be prescribed to HCV-infected
prisoners.
Community-based HCV peer workers can increase
engagement by people who inject drugs (PWID) with
HCV treatment services and reduce associated stigma
[29, 30]. Peer-based prison workers have the potential
to engage prisoners in healthcare and high levels of
support among staff and prisoners further underpin
the benefits [31–34].
This study reports on the feasibility and impact of a
peer-supported HCV screening and linkage-to-care
intervention to increase the numbers of HCV infections
detected—in particular new infections, linkage to care,
treatment engagement and treatment outcomes in the
IPS. While a small number of published studies have re-
ported on the effectiveness of HCV screening initiatives
in prisons [10], this study is unique both nationally and
internationally in evaluating a peer-supported HCV
screening initiative.
Methods
The IPS partnered with the European Commission Third
Health Programme funded ‘HepCare’ Project [35] to en-
hance screening and primary prevention for populations
at risk of HCV infection and specifically implementing an
enhanced HCV screening programme at Mountjoy Prison
in Dublin Ireland. Ethical approval was obtained from the
Mater Ethics Committee as part of the Seek and Treat
component of The European Hep Care Project and sup-
ported and endorsed by the IPS’s ethics group [36].
Setting
Mountjoy Prison is a large urban prison which at cap-
acity houses 538 sentenced male prisoners.
Peer workers in Irish prisons
For many years, the Irish Prison Service (IPS) and Irish
Red Cross have trained inmates in all Irish prisons as
community-based health volunteers. These prison-based
volunteers link with the formal prison health system and
act as peer educators to improve prison health and
safety. They are volunteers from the prison population
on enhance regimes (eligible for defined privileges) and
the programme is managed and governed by the Irish
Red Cross.
Intervention development
All Irish Red Cross prisoner volunteers (n = 14) were in-
vited to a focus group to discuss their experience of
HCV screening and treatment in prison and to provide
input into the design and implementation of this study.
A draft design of the proposed intervention was com-
pleted and presented to a larger implementation group
which included prison healthcare and custodial manage-
ment, prison officers, nurses and doctors and Irish Red
Cross staff overseeing the prison volunteer programme.
A researcher-administered questionnaire was devel-
oped and piloted by the research team in conjunction
with national experts in the area and prisoner groups.
The content of the questionnaire was informed by the
research tools used in the two previous prison-based
prevalence studies and the European ‘HepCare’ project
data collection tool [27, 28, 35].
The final intervention design included an awareness and
educational session for prison volunteers, educational post-
ers and leaflets as promotional materials, a risk-based ques-
tionnaire, provision of HCV screening and result disclosure,
referrals for on-site fibroscaning, and linkage to treatment.
Crowley et al. Harm Reduction Journal _#####################_ Page 2 of 10
Intervention
The peer-supported screening took place over three, 2-day
periods between March 2017 and August 2017. Throughout
the study intervention, peer workers accompanied prisoners
to the screening sites and promoted the pilot on the land-
ings. This element of the campaign was considered crucial
to the engagement of the prisoners in the process. All pris-
oners were offered BBV screening, but prisoners considered
to have severe mental illness undergoing active treatment
and prisoners considered to pose a security risk to the re-
search team were excluded from the study (identified by the
local medical team).
All study participants were given a patient information
leaflet and asked to sign a consent form. No induce-
ments were offered. Study participants were offered
blood-borne virus (BBV) testing. Results were given 4
weeks after screening. Results pertaining to prisoners
transferred or released were sent on to their relevant
medical practitioners. In-reach fibroscaning was avail-
able on-site for those found to have HCV infection on
screening. Prisoners with untreated chronic HCV infec-
tion who remained incarcerated at the study site were
referred to in-reach hepatology services for treatment.
All clinical data was transferred onto the patients’ elec-
tronic medical records.
Data collection
All prisoners who underwent HCV screening during the
peer-supported screening from March 2017 to August
2017 were eligible for inclusion in the study. Data was not
collected for all possible participants since the prison
population continually changed over this 6-month period.
Data on variables were collected from two sources: the
committal interview and the researcher-completed ques-
tionnaire. All prisoners routinely complete a nurse
committal interview on the day of incarceration which is
stored in the prisoners’ medical records in the Prison
Health Management System (PHMS). From this medical
review, we collected the following variables: age, country
of origin, history of drug and alcohol use, presence of
visible injecting marks and history of sharing needles.
The questionnaire included questions on age, country of
origin, incarceration history, drug use history and HCV
risk factors, including history of sharing needles and drug-
taking paraphernalia, history of tattooing and the sharing
of toothbrushes and razors while incarcerated.
Blood samples were sent to the National Virus Refer-
ence Laboratory (NVRL) and tested for HIV, HBV and
HCV antibodies. Reflex RNA and genotype testing were
performed on all HCV Ab +ve samples. A review of the
prisoners’ medical notes was conducted on prisoners
testing HCV Ab +ve and RNA negative to determine
those with SVR post-treatment and those with spontan-
eous clearance. This information was cross-checked with
the prisoner for accuracy. Twelve months’ follow-up
data on linkage to care and treatment outcomes was col-
lected from the participants’ electronic medical records.
Statistical analyses
All data were anonymised and coded, double-entered and
checked. Statistical review of the study was performed by a
biomedical statistician (EL), and analysis was conducted
using the Statistical Package for Social Sciences (version
23.0; SPSS UK Ltd.; Chersey, UK). Data were assessed for
normality and where necessary, data were log-transformed
for normalisation purposes. Data within tables are primarily
expressed as means (SD) or n (%).
Results
Demographics
A total of 425 male prisoners consented to participate in
the study. Study participants had a mean age of 32.8 years
and 92% reported Ireland as their country of origin. The
mean age of the first incarceration was 20 years, the mean
number of incarcerations was 6 and the mean total time
spent incarcerated was 7.7 years. Data from committal
interview showed that almost 50% of participants had a
past history of drug use. Of those who answered the ques-
tions on drug use in the risk questionnaire, 45% had a his-
tory of heroin use and 33% a history of IDU. The mean age
of first drug use was 15 years and first IDU was 20 years. In
terms of risk factors for HCV acquisition (data collected
from risk questionnaires), 34.5% gave a history of sharing
drug taking equipment (paraphernalia), 15.8% of sharing
needles in the community, 17.3% of having had a prison
tattoo and 14.2% a non-sterile community tattoo. Small
numbers reported sharing a razor or toothbrush in a prison
setting (4.2 % and 0.8% respectively). A total of 36.3% re-
ported having a history of methadone treatment, and the
mean length of time on treatment was 4.9 years (Table 1).
Screening results
Of the 425 prisoners who consented to participate, 419
had a successful serological HCV result. Eighty-seven
(21%) were HCV Ab +ve, 4 (1%) HIV Ab +ve and 3 (<
1%) HBV core Ab +ve. Of those who tested HCV Ab
+ve, 37 (43%) were HCV RNA −ve, of whom 27 (31%)
had self-cleared and 10 (27%) had SVR. The remaining
50 (57%) showed active HCV infection (HCV RNA +ve)
representing 12% of the entire study population (Fig. 1).
Comparison between self-declared status on committal
and serological result on peer-supported screening
The data on self-declared HCV status on committal (col-
lected from the committal interview on the prisoner’s elec-
tronic patient record) was grouped into declared HCV Ab
+ve on committal, declared HCVAb −ve on committal and
status unknown (never tested or status unknown). Of those
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screened, 48 (11%) self-declared HCVAb +ve at committal,
and on screening serology, 46 of whom were HCV Ab +ve,
showing a concordance of 96%. Of the 171 who declared
HCV Ab −ve on committal, 19 (4%) were HCV Ab +ve on
serology and eight (2%) were HCV RNA +ve (active infec-
tion). This demonstrates a concordance of 89%. Finally, for
those unaware of their status at committal, 22 (11%) were
HCV Ab +ve and 11 (5%) were HCV RNA + ve. A total of
19 (5% of the study participants screened) new active cases
of HCV infection (HCV RNA +ve) were identified through
peer-supported screening.
Linkage, assessment and treatment outcomes
Of the 50 prisoners with active HCV infection, 40 (80%)
had in-reach elastography performed. Of this cohort, 30
(75%) had scores < 8.5, five scores of 8.5 > 12.5 (fibrosis)
and five scores of ≥ 12.5 (cirrhosis). The outcomes for
linkage to care were grouped into three categories: HIV
co-infection who were already linked with specialist
hospital services (n = 4), linked with in-reach hepatology
nurse (either already linked or new referral) (n = 39) and
not linked with either of these services (due to release or
inter-prison transfer) (n = 7). Treatment outcomes were
reported as of September 2018 (> 12months after the
peer-supported screening) and under the following head-
ings: completed treatment with SVR, completed treatment
awaiting SVR, undergoing treatment, undergoing assess-
ment for treatment and linked to hospital services or com-
munity MMT (the study’s ethical approval did not allow
for data to be collected on prisoners after release).
For the HIV co-infected group, three had completed
treatment (two achieving SVR and one awaiting an SVR
result) and one was undergoing assessment for treat-
ment. Of those linked with in-reach hepatology services,
nine had completed treatment (eight achieving SVR and
one awaiting an SVR result), two are on treatment and
six are under assessment for treatment. Eighteen of this
group were referred to the hospital (St. James’), the
Table 1 Demographics of study participants from Mountjoy Prison (March to August 2017)
Variable Participant numbers Value n (%) Mean (SD)
Agea, b 425 32.8 (8.9)
Age of first incarcerationa 364 20.0 (7.1)
Episodes of incarcerationa 359 5.9 (8.3)
Total time incarcerated (years)a 361 7.7 (6.6)
Age of first drug usea 281 15.4 (7.7)
Age of first IV usea 106 20.1 (5.4)
Previous drug useb 409 199 (48.7)
Shared needlesb 406 26 (6.4)
Country of origin (n = 425)b
Ireland 389 (91.5)
West Europe 4 (0.9)
East Europe 22 (5.2)
Africa 10 (2.4)
HCV acquisition risk factors
History of heroin use 355 161 (45.4)
History of IV use 341 111 (32.6)
Shared needle community 342 54 (15.8)
Shared equipment 344 120 (34.9)
Shared razor in prison 357 15 (4.2)
Shared toothbrush in prison 358 3 (0.8)
Prison tattoo 358 62 (17.3)
Unsterile tattoo community 346 49 (14.2)
Opioid substitution treatment
Methadone treatment history 342 124 (36.3)
Length of time on methadone maintenance treatment 101 4.9 (6.6)
SD standard deviation, IV intravenous, HCV hepatitis C virus
aValues are means (± SD) for continuous variables or n (%) for categorical variables
bData from committal interview
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community location of the specialist hepatology services
that provides in-reach to the IPS. Of the final group, five
were formally linked to community MMT services and
two were lost to follow-up. In summary of the 50 pris-
oners identified with active HCV infection, 43 were
linked to specialist services and of this group, 12 had
completed treatment, 10 achieving SVR, two were under
treatment and eight were being assessed. Eighteen of this
group had a formal direct referral to the hospital setting
providing the in-reach hepatology service (Fig. 2).
Discussion
This unique Irish prison-based study found that peer-
supported screening is a feasible active HCV case-finding
intervention in a prison setting. It is a convincing example
of the benefits of a collaborative prison health intervention
using peer-to-peer health promotion and the WHO rec-
ommended a complete prison approach to planning and
implementation [37]. It was successful in testing a large
number of prisoners for HCV infection (n = 419). It also
had the added benefit of testing this cohort for HIV and
HBV infection and BBVs with high prevalence in prison
populations [2, 38].
Over half of the study population had a history of drug
use, with significant numbers having a history of heroin
use and IDU. These figures are similar to other Irish and
international studies and reflect the over-representation
of PWID in prison populations globally due to the on-
going criminalisation of this underserved and margina-
lised group [2, 27]. This study also found high levels of
self-reported known HCV risk behaviours in this prison
cohort including IDU, sharing needles and other drug-
taking paraphernalia and having a prison or non-sterile
community tattoo [2, 5, 39]. Peer-supported screening
identified 50 cases (12% of the study population) of ac-
tive untreated HCV infection of which 19 (5% of the
study population) had not been identified at committal.
These findings support the public health focus on
prisons as key locations to increase HCV diagnosis, link-
age to care and treatment [4, 25, 40]. It also supports
the ongoing need to increase harm reduction services
(opioid substitution treatment and needle and syringe
programmes) within prisons to reduce the risks of BBV
transmission in closed settings [41, 42].
The use of peer-supported screening as an active HCV
case-finding intervention has not been described previously
in the literature [25]. This intervention is a provider rather
than client-initiated, a factor which is known to improve
uptake [25]. It is an intervention that can be used in prison
populations who are already incarcerated and not just for
those entering prison. Evidence suggests that screening of-
fered within the first 24 h of committal has a better uptake
Fig. 1 Peer-supported screening outcomes from Mountjoy Prison, Dublin, Ireland (March 2017 to August 2017)
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than screening offered later in the custodial sentence or just
at pre-release [16, 25]. It is important to remember that ef-
forts to scale up HCV screening and treatment in prisons
are a very recent public health intervention and many pris-
oners globally have been incarcerated since this approach
has been more widely adopted. Because of the ongoing risk
of HCV transmission during incarceration, updated inter-
national guidelines recommend the repeat screening of all
prisoners yearly which will require different strategies than
those for screening new entrants to prison [9, 16, 25]. Peer-
supported screening has the potential to be utilised in these
situations.
The use of peers to design, support and implement is
intrinsic to this study intervention. Prisoners are identi-
fied as a hard-to-reach population, and even in prisons
with easier access to healthcare, many still do not en-
gage. There is often a lack of trust between prisoner
and staff, and prisoners have identified the fear of
stigma as being a key barrier to engagement in the
HCV cascade of care [43–45]. The benefits of peer in-
volvement in community HCV care are well docu-
mented [30, 46–50]. Peer workers can dispel the myths
and fears associated with HCV treatment, reduce
stigma, enhance mutual trust, increase social support
and increase knowledge and engagement in HCV care
[30, 50].
Studies have shown that peer workers have a positive
impact on the uptake of HCV services and have high
levels of satisfaction among service users and staff [46,
51]. There is further evidence to suggest that engagement
in HCV care may be facilitated by the influence of peers
who completed treatment. The ETHOS study in Australia
reported a very strong positive response to peer workers
by staff and service users which lead to improved access
to services, a more client-friendly treatment environment
and increased support to services users with assessment
and engagement with HCV treatment [30].
A 2016 systematic review of peer education and
support in prison settings found that peer education
interventions are effective at reducing risk behaviour,
acceptable within the prison environment and have a
positive impact on prisoner wellbeing [52]. Peer
workers are a credible source of information and have
the ability to connect with other prisoners, reduce so-
cial stigma and impact positively with a vulnerable
patient cohort who is traditionally resistant to profes-
sional advice [31]. There are also direct benefits for
the peer workers themselves and benefits for the
Fig. 2 Peer-supported screening—untreated chronic infection outcomes from Mountjoy Prison, Dublin, Ireland (September 2018). HCV hepatitis C
virus, PCR polymerase chain reaction, kPa kilopascal, HIV human immunodeficiency virus, SVR sustained virological response, MMT methadone
maintenance treatment
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wider prison system including more effective use of
resources and the ability to expand the range of
prison-based health services available to inmates [51].
This study identified peer workers as an enabler to
prisoners engaging in HCV screening and treatment
and reducing stigma.
A number of community-based studies have reported
on the concordance between perceived HCV status and
actual status in PWID [53]. Similar to these studies, this
study found high levels of concordance between self-
declared and serological HCV status. There was a 96%
concordance for those who declared being positive and
89% for those who declared being negative. These findings
are contrary to a 2000 Irish study that found self-declared
HCV status as unreliable with 37% of those declaring
negative being positive on oral swab testing [54]. The dif-
ference in findings may be accounted for by the increased
numbers attending and the high rates of HCV testing in
community drug treatment services in Ireland. The find-
ings from this evaluation suggest that prisoners can be di-
rected into different care pathways based on self-declared
status at committal. This may reduce assessment times
and improve linkage to care and treatment outcomes an
important consideration in prisons where the majority of
prisoners serve short sentences [18, 19].
The discordant findings, despite low numbers, are a
concern given they represent potential HCV infection
risk and re-enforce the need for regular testing and re-
testing of prison populations. These findings also high-
light the need to improve how we collect HCV data on
individuals and populations. HCV-infected people often
are unaware of the difference between past infection,
chronic infection, active infection, self-clearance, SVR
and re-infection. This lack of clarity is also shown in
population HCV surveillance data. Historically HCV
prevalence data in prison populations was reported as
HCV Ab + prevalence, some more recent studies have
reported on HCV RNA + prevalence (current active in-
fection) [1, 2, 55]. As we scale up HCV treatment, it is
important that serological markers are matched with
clinical data so that we can measure levels of active un-
treated infection, treated infection and re-infections.
Furthermore, it is important that HCV-infected persons
are educated on the different phases of HCV infection
and their associated blood markers so that they can pro-
vide accurate medical information to healthcare staff. In-
creased accuracy could reduce the need for unnecessary
and expensive repeat screening.
This study reports high-levels of linkage to care for
prisoners identified as having untreated HCV infection.
The presence of the specialist in-reach hepatology nurse
facilitated this process with nearly 80% linked with this
service. The use of specialist nurses in prison has previ-
ously been identified as a facilitator to HCV screening
and treatment in prison settings [23, 43]. Treatment out-
comes were impacted by a national decision to curtail
DAA access to those with advanced liver disease in June
2017. This restriction was lifted in February 2018. The
treatment outcomes reported in this study support pre-
viously published findings that prisoners (including co-
infected with HIV) can be successfully treated for HCV
with outcomes similar to or better than other population
groups [56, 57]. Many of the HCV-infected participants
identified required linkage to hospital-based specialist
services on release. This finding underpins the need to
support prisoners transitioning back into the community
where a range of competing priorities can impact on
their ability to link with these services [58, 59]. This
transition between prison and community is identified
as a high-risk period for PWID and pivotal to HCV
treatment uptake, prevention and elimination [19, 60].
This model involved the linking of prisoners not started
on treatment to the specialist hospital service that pro-
vides in-reach hepatology services to the IPS. It was
hoped that this approach might increase uptake in the
community since the specialist nurse was common to
both locations and would be known to the patient.
The use of HCV serology markers and current fibroscan
scores are strengths of this study. The large numbers
screened and followed 12months later is a further
strength of this unique study. There are a number of limi-
tations to this study including it being male only and sin-
gle site, which reduces its generalisability. A further
limitation of this study is that it is observational in design
and does not have a comparative arm. Comparing the ef-
fectiveness of different active HCV case-finding models
would increase the utility of its findings, but the imple-
mentation of such a study design in a large working prison
is difficult. Consent to follow up prisoners on release to
the community would have benefitted the study’s findings.
Data on the cost-effectiveness of this model is currently
underway and will be published at a later date.
Conclusion
Large numbers of Irish male prisoners having a history of
IDU are frequently incarcerated from a young age and
have multiple risk factors for HCV acquisition. A peer-
supported screening initiative is both a feasible and an ac-
ceptable model of active HCV case finding in a prison set-
ting. This model identified 50 cases of untreated active
HCV infection of which 19 had not been identified at
committal. Prison-based hepatology nurse specialist facili-
tated the linking of 39 active HCV-infected prisoners to
HCV assessment and care. Prisoners can be successfully
treated in prison settings, but significant numbers will still
require linkage to community HCV treatment services.
Supporting prisoners while transitioning to the commu-
nity is key to optimising HCV management. There is a
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high concordance between prisoners’ self-declared HCV
status and serology status at committal. This finding sup-
ports the devolvement of HCV treatment pathways based
on self-declared HCV status which could reduce assess-
ment time and linkage to treatment particularly for the
large numbers of prisoners who serve short prison sen-
tences. The complexities of prison environments re-
quire a planned and coordinated approach to HCV
care to optimise outcomes. Incarceration offers an
ideal public health opportunity to engage with and
support a high-risk group of HCV-infected PWID
with prison and community-based health services.
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